Related Experiment Video
Updated: Aug 1, 2026
08:03
Intracavernosal Pressure Recording to Evaluate Erectile Function in Rodents
Published on: June 6, 2018
Experience with triple-drug therapy in a pharmacological erection program
F E Govier1, R D McClure, R M Weissman
1Department of Urology, Virginia Mason Medical Center, Seattle, Washington.
The Journal of Urology
|December 1, 1993
Summary
Triple-drug therapy, a combination of papaverine, phentolamine, and prostaglandin E1, effectively treats erectile dysfunction. This approach demonstrated a low incidence of side effects like priapism, pain, and scarring in a clinical study.
Area of Science:
- Urology
- Andrology
- Pharmacology
Background:
- Erectile dysfunction (ED) affects a significant number of men.
- Pharmacological interventions are a key component in managing ED.
- Intracorporeal injections offer a direct treatment method for ED.
Purpose of the Study:
- To evaluate the efficacy and safety of triple-drug therapy for erectile dysfunction.
- To assess the long-term outcomes of intracorporeal triple-drug therapy.
- To determine the optimal agent for pharmacological erection programs.
Main Methods:
- A cohort of 170 impotent men received intracorporeal injections of papaverine, phentolamine, and prostaglandin E1.
- 146 patients were enrolled in a long-term pharmacological erection program.
- Data on injection volume, duration of treatment, and adverse events were collected.
Main Results:
- Usable erections were achieved in all participants.
- The average treatment duration was 11.2 months.
- Low incidences of priapism (1.7%), scarring (4.2%), and pain (3.5%) were reported.
Conclusions:
- Triple-drug therapy is an effective and safe treatment for erectile dysfunction.
- The combination offers a superior dose response with minimal adverse effects.
- This therapy is recommended as a primary agent in pharmacological ED management.
Related Concept Videos
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:26Drug Administration and Therapy Phases: Overview
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications